Study by the Universities of Bonn and Ulm investigates how a cellular mechanism can be used for other purposes
An international team of researchers led by the Universities of Bonn and Ulm, Germany, has investigated how a cell’s own “protein shredder” can be specifically programmed to fight cancer.
The researchers were able to demonstrate the degradation of proteins that are overly active in breast cancer, for example.
The results are published in the renowned journal Chemical Science.
Cells continuously produce proteins to be able to carry out their tasks in the body.
Any protein molecules that are no longer needed are given a kind of “disposal sticker”.
All proteins with such a label are then crushed and recycled by a cell’s own shredder, the proteasome.
For some years, researchers have been trying to harness this mechanism selectively in the fight against diseases such as cancer.
After all, tumour cells also require certain proteins.
If it was possible to attach a disposal label to them, they would inevitably be shredded by the proteasome, which would inhibit the growth of the cancer cell.
This approach has indeed already proven to be effective in the test tube.
Here, scientists use so-called PROTACs (the abbreviation stands for “proteolysis targeting chimeras”).
“However, producing these substances is very complicated,” explains Prof. Dr. Michael Gütschow from the Pharmaceutical Institute of the University of Bonn. “We have investigated which strategies are promising in this respect and how particularly effective PROTACs can be customised, so to speak.”
PROTACs are molecular hybrids: They consist of both a molecular part that docks to the cancer protein, as well as a structure that can bind to the labelling enzymes.
Both units are connected by a kind of arm.
PROTACs thus bring the target protein and the labelling machine together, thereby ensuring that the harmful protein is given a disposal label.
“We have synthesised many molecules, among other things to find out what structure and length the arm must have in order to label the protein as effectively as possible,” explains Christian Steinebach from the Pharmaceutical Institute of the University of Bonn.
In addition, the researchers optimised another aspect of the PROTACs.
Each cell has dozens of different labelling enzymes called ubiquitin ligases.
Not all of them work equally well with every protein.
“We have therefore produced and tested different PROTACs for different ligases,” says Dr. Jan Krönke from Ulm University Medical Center.
The active substances developed target a protein that ensures that cancer cells can multiply better.
The PROTACs now cause the cell’s own shredder to destroy the protein.
“In experiments with cell cultures, we were able to show that our PROTACs actually significantly reduce the cellular concentration of this protein and effectively suppress the growth of cancer cells,” explains Dr. Krönke. “The substances now allow us to study proteins that are important for the tumour in more detail.”
The universities of Bonn and Ulm are among the leading institutions in Germany in the young field of PROTAC research.
“Our study shows prototypically which techniques can be used to produce and specifically optimise these active substances,” says Gütschow.
There is great interest in such strategies, since PROTACs are regarded as an important beacon of hope for the treatment of serious diseases.
Source: University of Bonn